News
Gene therapy for sickle cell disease may help improve a major contributing factor to stroke risk in patients, reports a new ...
T cells are a natural part of the immune system designed to fight infections and cancer, but in conditions like blood cancer, they may not be able to eliminate malignant cells, according to Dr.
The findings were published today in the American Journal of Hematology. Improving blood flow in the brain with gene therapy A small but significant percentage of patients with sickle cell disease are ...
Read Ino’s inspiring cancer journey and discover how cutting-edge treatments and pediatric clinical trials are providing hope ...
5d
MedPage Today on MSNCyclophosphamide for GVHD Continues to Extend Stem-Cell Transplant EligibilityPatients who underwent stem cell transplants (SCTs) involving mismatched unrelated donors (MMUDs) had a 1-year overall ...
FDA approved label changes for Breyanzi and Abecma, easing access by reducing monitoring rules and eliminating REMS safety ...
Blood cancer patients who may have previously struggled to find a donor for transplantation now have more options. A new ...
June brought major blood cancer updates, and CURE is sharing the latest in myelofibrosis treatment and FDA breakthroughs, as ...
Protagonist Therapeutics Inc. (NASDAQ:PTGX) is one of the best mid cap growth stocks to invest in now. Just as June began, Protagonist Therapeutics and Takeda Pharmaceutical Company Limited (NYSE:TAK) ...
Specifically, the FDA removed the Risk Evaluation and Mitigation Strategy (REMS) program requirements from two BCMA-directed CAR T-cell therapies for multiple myeloma — ciltacabtagene autoleucel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results